会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明授权
    • Piperidine derivatives as neurotransmitter re-uptake inhibitors
    • 哌啶衍生物作为神经递质再摄取抑制剂
    • US06376673B1
    • 2002-04-23
    • US09415227
    • 1999-10-12
    • Peter MoldtFrank WatjenJorgen Scheel-Kruger
    • Peter MoldtFrank WatjenJorgen Scheel-Kruger
    • C07D21118
    • C07D211/28
    • The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salt thereof; wherein R is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl or 2-hydroxyethyl; R3 is —CR′═NOR″ wherein R′ and R″ each independently are hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, cycloalkylalkenyl, alkynyl, cycloalkylalkynyl, aryl or benzyl; R4 is phenyl which may be substituted one or more times with substituents selected from the group consisting of halogen, CF3, CN, amino, nitro, alkoxy, cycloalkoxy, alkyl, cycloalkyl, alkenyl, alkynyl, aryl and heteroaryl; 3,4-methylenedioxyphenyl; benzyl which may be substituted one or more times with substituents selected from the group consisting of halogen, CF3, CN, amino, nitro, alkoxy, cycloalkoxy, alkyl, cycloalkyl, alkenyl, alkynyl, aryl and heteroaryl; heteroaryl which may be substituted one or more times with substituents selected from the group consisting of halogen, CF3, CN, amino, nitro, alkoxy, cycloalkoxy, alkyl, cycloalkyl, alkenyl, alkynyl, aryl and heteroaryl; or naphthyl which may be substituted one or more times with substituents selected from the group consisting of halogen, CF3, CN, amino, nitro, alkoxy, cycloalkoxy, alkyl, cycloalkyl, alkenyl, alkynyl, aryl and heteroaryl. The compounds possess valuable pharmaceutical properties as monoamine neurotransmitter, i.e. dopamine, serotonin, noradrenaline, reuptake inhibitors.
    • 本发明涉及式(I)化合物或其药学上可接受的盐; 其中R是氢,烷基,烯基,炔基,环烷基,环烷基烷基或2-羟乙基; R3是-CR'= NOR“,其中R'和R”各自独立地为氢,烷基,环烷基,环烷基烷基,烯基,环烷基烯基,炔基,环烷基炔基,芳基或苄基; R4是可以被选自卤素,CF 3,CN,氨基,硝基,烷氧基,环烷氧基,烷基,环烷基,烯基,炔基,芳基和杂芳基的取代基取代一次或多次的苯基; 3,4-亚甲二氧基苯基; 苄基,其可以被选自卤素,CF 3,CN,氨基,硝基,烷氧基,环烷氧基,烷基,环烷基,烯基,炔基,芳基和杂芳基的取代基取代一次或多次; 可以被选自卤素,CF 3,CN,氨基,硝基,烷氧基,环烷氧基,烷基,环烷基,烯基,炔基,芳基和杂芳基的取代基取代一次或多次的杂芳基; 或萘基,其可以被选自卤素,CF 3,CN,氨基,硝基,烷氧基,环烷氧基,烷基,环烷基,烯基,炔基,芳基和杂芳基的取代基取代一次或多次。 该化合物具有作为单胺神经递质(即多巴胺,5-羟色胺,去甲肾上腺素,再摄取抑制剂)的有价值的药物性质。
    • 5. 发明授权
    • Fused indole and quinoxaline derivatives, their preparation and use
    • 熔融吲哚和喹喔啉衍生物,其制备和使用
    • US5801174A
    • 1998-09-01
    • US809086
    • 1997-05-20
    • Peter MoldtFrank Watjen
    • Peter MoldtFrank Watjen
    • A61K31/40A61K31/407A61K31/435A61K31/437A61K31/55A61P9/00A61P9/08A61P9/10A61P25/00A61P25/04A61P25/08A61P25/16A61P25/18A61P25/20A61P25/22A61P25/28A61P25/30A61P39/02C07D471/04C07D487/04A61K31/495
    • C07D471/04C07D487/04
    • The present patent application discloses compounds having the formula ##STR1## or a pharmaceutically acceptable salt thereof wherein R.sup.1 is hydrogen, alkyl or benzyl; X is O or NOR.sup.2, wherein R.sup.2 is hydrogen, alkyl or benzyl; Y is N--R.sup.4 wherein R.sup.4 is hydrogen, OH or alkyl; n is 0 or 1; R.sup.6 is phenyl which is substituted one or more times with substituents selected from the group consisting of SO.sub.2 NR'R", CONR'R", and COR'" wherein R' and R" each independently are hydrogen, alkyl, or --(CH.sub.2).sub.p --W, wherein p is 0, 1, 2, 3, 4, 5, or 6, and W is hydroxy, amino, alkoxycarbonyl, or phenyl which may be substituted one or more times with substituents selected from the group consisting of halogen, CF.sub.3, NO.sub.2, amino, alkyl, alkoxy or methylenedioxy; or wherein R' and R" together is (CH.sub.2).sub.r Z(CH.sub.2).sub.s wherein r and s each independently are 0, 1, 2, 3, 4, 5, or 6 and Z is O, S, CH.sub.2 or NR"" wherein R"" is hydrogen, alkyl, or --(CH.sub.2).sub.p --W, wherein p is 0, 1, 2, 3, 4, 5, or 6, and W is hydroxy, amino, alkoxycarbonyl, or phenyl which may be substituted one or more times with substituents selected from the group consisting of halogen, CF.sub.3, NO.sub.2, amino, alkyl, alkoxy or methylenedioxy; and wherein R'" is hydrogen, alkyl, alkoxy or phenyl which may be substituted one or more times with substituents selected from the group consisting of halogen, CF.sub.3, NO.sub.2, amino, alkyl, alkoxy or methylenedioxy; A is a ring of five to seven atoms fused with the benzo ring at the positions marked a and b. The compounds are useful in the treatment of cerebrovascular disorders for example.
    • PCT No.PCT / EP95 / 03594 371日期1997年5月20日 102(e)日期1997年5月20日PCT提交1995年9月12日PCT公布。 出版物WO96 / 08495 日本特开1996年3月21日本专利申请公开了具有式“IMAGE”的化合物或其药学上可接受的盐,其中R 1是氢,烷基或苄基; X是O或NOR2,其中R2是氢,烷基或苄基; Y是N-R4,其中R4是氢,OH或烷基; n为0或1; R6是被选自SO2NR'R“,CONR'R”和COR“的取代基一次或多次的苯基,其中R'和R”各自独立地是氢,烷基或 - (CH 2)p W,其中p是0,1,2,3,4,5或6,并且W是羟基,氨基,烷氧基羰基或苯基,其可以被选自以下的取代基取代一次或多次: 的卤素,CF 3,NO 2,氨基,烷基,烷氧基或亚甲二氧基; 或其中R'和R“一起是(CH 2)rZ(CH 2)s,其中r和s各自独立地是0,1,2,3,4,5或6,Z是O,S,CH 2或NR' “其中R”“是氢,烷基或 - (CH 2)p W,其中p是0,1,2,3,4,5或6,并且W是羟基,氨基,烷氧基羰基或苯基 其可以被选自卤素,CF 3,NO 2,氨基,烷基,烷氧基或亚甲二氧基的取代基取代一次或多次; 并且其中R“是氢,烷基,烷氧基或苯基,其可以被选自卤素,CF 3,NO 2,氨基,烷基,烷氧基或亚甲二氧基的取代基取代一次或多次; A是在标记a和b的位置与苯环稠合的5至7个原子的环。 该化合物可用于治疗例如脑血管障碍。
    • 10. 发明授权
    • Isatinoxime derivatives, their preparation and use
    • 伊马替尼衍生物,其制备和用途
    • US5242918A
    • 1993-09-07
    • US936579
    • 1992-08-27
    • Frank WatjenBjarne H. DahlJorgen DrejerLeif H. Jensen
    • Frank WatjenBjarne H. DahlJorgen DrejerLeif H. Jensen
    • C07C205/45C07D471/04C07D487/04C07D491/04C07D491/048C07D495/04
    • C07D471/04C07C205/45C07D487/04C07D491/04C07D495/04
    • A compound having the formula ##STR1## wherein R.sup.4 and R.sup.5 independently are hydrogen, halogen, CF.sub.3, CN, NO.sub.2 or SO.sub.2 NR.sup.1 R.sup.2 whereinR.sup.1 is hydrogen or straight, C.sub.1-6 -alkyl which may be branched or cyclic,R.sup.2 is hydrogen or straight, C.sub.1-6 -alkyl which may be branched or cyclic,or wherein R.sup.1 and R.sup.2 together represent --(CH.sub.2).sub.n --A--(CH.sub.2).sub.m --, wherein A is O, S, CH.sub.2 or NR.sup.I, wherein R.sup.I is H, C.sub.1-6 -alkyl which may be straight, branched or cyclic, n is 0, 1, 2, 3, 4, 5 and m is 0, 1, 2, 3, 4, 5;Q is NOH or O;Z=O, S, N--R.sup.II, ##STR2## wherein R.sup.II, R.sup.III, R.sup.IV and R.sup.V independently are hydrogen, benzyl, C.sub.1-6 carboxylic acid-acyl, C.sub.1-6 -alkoxy which may be branched or cyclic, or C.sub.1-6 -alkyl which may be branched or cyclic;X is --(CH.sub.2).sub.o -- wherein o is 0, 1, 2, or 3;Y is --(CH.sub.2).sub.p -- wherein p is 0, 1, 2 or 3;.alpha. and .beta. indicate attachment points,and a method of treating disorders of a mammal, including a human, responsive to the blockade of glutamic and aspartic acid receptors, with the same.
    • 具有式“IMAGE”的化合物,其中R 4和R 5独立地是氢,卤素,CF 3,CN,NO 2或SO 2 NR 1 R 2,其中R 1是氢或直链,可以是支链或环状的C 1-6 - 烷基,R 2是氢或直链, 可以是支链或环状的C 1-6 - 烷基,或其中R 1和R 2一起表示 - (CH 2)nA-(CH 2)m - ,其中A是O,S,CH 2或NRI,其中R 1是H,C 1-6 - 烷基,其可以是直链,支链或环状的,n为0,1,2,3,4,5,m为0,1,2,3,4,5; Q是NOH或O; Z = O,S,N-RII,其中RII,RIII,RIV和RV独立地是氢,苄基,C1-6羧酸 - 酰基,可以是支链或环状的C1-6 - 烷氧基或C1-6 可以是支链或环状的 - 烷基; X是 - (CH 2)o - ,其中o是0,1,2或3; Y是 - (CH 2)p - ,其中p是0,1,2或3; α和β表示连接点,以及一种治疗对谷氨酸和天冬氨酸受体的封闭有反应的哺乳动物(包括人)的病症的方法。